PROK ProKidney Corp.
Financings ·
ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.
Jefferies earns up to 3.0% of gross proceeds on the new $200,000,000 program. The stock last sold at $4.54 on July 11, 2025, and the second dosing group in the Phase 2 REGEN-007 trial missed statistical significance.
ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $114.1 million | $127.7 million |
| Net income (loss) | -$69.0 million | -$61.2 million |
| Cash from operations | -$120.1 million | -$126.4 million |
| Cash and equivalents | $108.5 million | $99.1 million |
Our latest story on this, dated Jul 14, 2025: "ProKidney sets up at-the-market program for up to $200,000,000 of stock with Jefferies". The story links the filing or release it is based on. Read the story.
ProKidney Corp. trades under the ticker PROK on NASDAQ.
ProKidney Corp. is listed on NASDAQ. Our directory also records these other listings: BIVA:PROK; BMV:PROK.
The SEC Central Index Key (CIK) for ProKidney Corp. is 1850270. Its filings are on SEC EDGAR.
Our directory records ProKidney Corp. under United States.
Our directory classifies ProKidney Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ProKidney Corp. is US74291D1046.
aibio.space lists ProKidney Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
ProKidney Corp. reported a net loss of $69.0 million for the fiscal year ended Dec 31, 2025, and used $120.1 million of cash in operations, per its annual report to the SEC.
$114.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$74.9 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on ProKidney, dated Oct 29, 2026: "ProKidney files $650 million shelf with $200 million Jefferies sales program". ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026. Source.
From our story of Oct 29, 2026: Cash, losses and the going concern language Source.
Our latest merger story, dated Mar 31, 2025: "ProKidney files to move incorporation from the Cayman Islands to Delaware". ProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent. Source.
Reported a financing. SEC Form S-3. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Filed documents for a merger or acquisition. SEC Form S-4. Source
Reported a financing. SEC Form 8-K (Items 1.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio